WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO) www.neurometrix.com, a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, reported today that it will be an exhibitor and sponsor at the 14th Malvern Diabetic Foot Conference on May 9-11, 2012 in Malvern, United Kingdom, at the Abbey Hotel.
“We are pleased to be invited as an exhibiting sponsor to this premier diabetes conference,” said Shai N. Gozani, M.D., Ph.D., President and Chief Executive Officer, NeuroMetrix. “This conference draws highly-regarded diabetes professionals and represents an opportunity for NeuroMetrix to meet with international leaders and discuss our diabetes program including NC-stat® DPNCheck™, our fast, accurate, and quantitative point-of-care test for diabetic peripheral neuropathy (DPN).”
Dr. Kenneth Snow, NeuroMetrix Chief Medical Officer, will be in attendance at the conference.
Started in 1986, the Malvern Diabetic Foot Conference is the longest-standing international diabetic foot meeting held globally every other year. The event brings together experts on the diabetic foot from up to 30 countries, predominantly North America and Western Europe. Attendance is limited to 250 people and includes physicians, surgeons, podiatrists, orthotists and nursing staff with a common interest in diabetic foot problems. For more information, please visit http://www.malverndiabeticfoot.org/.
About NeuroMetrix
NeuroMetrix is an innovative medical device company that develops and markets home use and point-of-care devices, associated consumables, and support software for the treatment and management of diabetes and its complications. The company is focused on nerve related complications of diabetes, called diabetic neuropathies, which affect over 50% of people with diabetes. If left untreated, diabetic neuropathies trigger foot ulcers that may require amputation, cause disabling pain, and increase the risk of falling in the elderly. The annual cost of diabetic neuropathies has been estimated at $14 billion in the United States. The company’s products are used by physicians and other clinicians, in retail health settings such as pharmacies, and by managed care organizations to optimize patient care and reduce healthcare costs. The company markets the NC-stat® DPNCheck™ device, which is a rapid, accurate, and quantitative point-of-care test for diabetic neuropathy. This product is used to detect diabetic neuropathy at an early stage and to guide treatment. The company is in late stage development of SENSUS™, a pain management device that will be used to treat painful diabetic neuropathy, a form of chronic intractable pain. Currently, painful diabetic neuropathy is treated pharmacologically, which is a $2 billion annual market. The company has additional therapeutic products in its pipeline. For more information, please visit http://www.neurometrix.com.